Myovant Sciences announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for… read more.
Merck Inc announced results from two initial Phase III studies evaluating the safety, tolerability and immunogenicity of V 114, the company’s investigational 15-valent pneumococcal conjugate vaccine for pneumococcal… read more.
Principia Biopharma Inc. announced that the first patient has been enrolled in its partner Sanofi’s Phase III clinical trial of SAR 442168 in patients with relapsing multiple sclerosis… read more.
Glenmark Pharmaceuticals announced the launch of antiviral drug FabiFlu (favipiravir) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
